# EDGAR Filing Document

**Accession Number:** 0001534969
**File Stem:** 0001534969-23-000032
**Filing Date:** 2023-3
**Character Count:** 25750
**Document Hash:** 0af1f6b2ad2c3d6d4cd43200bbb396c8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001534969-23-000032.hdr.sgml**: 20230322

**ACCESSION NUMBER**: 0001534969-23-000032

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230322

**DATE AS OF CHANGE**: 20230322

**EFFECTIVENESS DATE**: 20230322

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SERA PROGNOSTICS, INC.
- **CENTRAL INDEX KEY:** 0001534969
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 261911522
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270746
- **FILM NUMBER:** 23753193

**BUSINESS ADDRESS:**
- **STREET 1:** 2749 E. PARLEYS WAY
- **STREET 2:** SUITE 200
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84109
- **BUSINESS PHONE:** (801) 990-0520

**MAIL ADDRESS:**
- **STREET 1:** 2749 E. PARLEYS WAY
- **STREET 2:** SUITE 200
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84109

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Sera Prognostics, Inc.** 

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **26-1911522** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification Number)** |

---

**2749 East Parleys Way**

**Suite 200<br>Salt Lake City, UT 84109**

**Telephone: (801) 990-0520**

**(Address, including zip code, and telephone number, including area code,** 

**of registrant's principal executive offices)**

**2021 Equity Incentive Plan**

**2021 Employee Stock Purchase Plan**

**(Full Title of the Plans)**

**Gregory C. Critchfield, M.D., M.S.**

**President and Chief Executive Officer**

**Sera Prognostics, Inc.**

**2749 East Parleys Way**

**Suite 200**

**Salt Lake City, UT 84109**

**Telephone: (801) 990-0520**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | □ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
| | | Emerging growth company | ⌧ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement registers 1,184,507 additional shares of Class A Common Stock, par value $0.0001 per share ("Common Stock"), of Sera Prognostics, Inc. (the "Registrant") under the Registrant's 2021 Equity Incentive Plan (the "2021 Plan") and 296,126 additional shares of Common Stock under the Registrant's 2021 Employee Stock Purchase Plan (the "ESPP"), representing an increase of 1,184,507 shares of Common Stock reserved for issuance under the 2021 Plan and 296,126 shares of Common Stock reserved for issuance under the ESPP, in each case effective January 1, 2023 by operation of the "evergreen" provision contained in the applicable plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File Nos. 333-258696 and 333-263943). The information contained in the Registrant's registration statement on Form S-8 (File No. 333-258696), except for "Item 8 Exhibits," is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. &nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit Number** | **Exhibit Description** | **Filed Herewith** | **Incorporated by Reference herein from Form or Schedule** | **Filing Date** | **SEC File/Reg. Number** |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-1.htm)</u> | <u>[Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-1.htm)</u> |  | <u>[Form 8-K (Exhibit 3.1)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-1.htm)</u> | <u>[7/20/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-1.htm)</u> | <u>[001-40606](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-1.htm)</u> |
| <u>[4.2](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-2.htm)</u> | <u>[Restated Bylaws](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-2.htm)</u> |  | <u>[Form 8-K (Exhibit 3.2)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-2.htm)</u> | <u>[7/20/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-2.htm)</u> | <u>[001-40606](https://www.sec.gov/Archives/edgar/data/1534969/000110465921094030/tm2122556d1_ex3-2.htm)</u> |
| <u>[4.3](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex4-1.htm)</u> | <u>[Specimen Common Stock Certificate](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex4-1.htm)</u> |  | <u>[Form S-1/A (Exhibit 4.1)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex4-1.htm)</u> | <u>[7/8/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex4-1.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex4-1.htm)</u> |
| <u>[4.4](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-2.htm)</u> | <u>[Form of Common Stock Purchase Warrant - I](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-2.htm)</u> |  | <u>[Form S-1 (Exhibit 4.2)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-2.htm)</u> | <u>[6/11/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-2.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-2.htm)</u> |
| <u>[4.5](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-3.htm)</u> | <u>[Form of Common Stock Purchase Warrant - II](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-3.htm)</u> |  | <u>[Form S-1 (Exhibit 4.3)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-3.htm)</u> | <u>[6/11/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-3.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-3.htm)</u> |
| <u>[4.6](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-4.htm)</u> | <u>[Form of Series E Warrant](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-4.htm)</u> |  | <u>[Form S-1 (Exhibit 4.4)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-4.htm)</u> | <u>[6/11/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-4.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-4.htm)</u> |
| <u>[4.7](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-5.htm)</u> | <u>[Fourth Amended and Restated Investors' Rights Agreement, dated as of February 23, 2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-5.htm)</u> |  | <u>[Form S-1 (Exhibit 4.5)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-5.htm)</u> | <u>[6/11/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-5.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921080206/tm2110724d11_ex4-5.htm)</u> |
| <u>[4.8](https://www.sec.gov/Archives/edgar/data/0001534969/000153496922000034/sera-20211231x10kxex46.htm)</u> | <u>[Description of Securities](https://www.sec.gov/Archives/edgar/data/0001534969/000153496922000034/sera-20211231x10kxex46.htm)</u> |  | <u>[Form 10-K (Exhibit 4.6)](https://www.sec.gov/Archives/edgar/data/0001534969/000153496922000034/sera-20211231x10kxex46.htm)</u> | <u>[3/29/2022](https://www.sec.gov/Archives/edgar/data/0001534969/000153496922000034/sera-20211231x10kxex46.htm)</u> | <u>[001-40606](https://www.sec.gov/Archives/edgar/data/0001534969/000153496922000034/sera-20211231x10kxex46.htm)</u> |
| <u>[5.1](sera-2023formsx8xexhibit51.htm)</u> | <u>[Opinion of](sera-2023formsx8xexhibit51.htm)</u><u>[Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.](sera-2023formsx8xexhibit51.htm)</u> | <u>[X](sera-2023formsx8xexhibit51.htm)</u> |  |  |  |
| <u>[23.1](sera-2023formsx8xexhibit231.htm)</u> | <u>[Consent of Independent Registered Public Accounting Firm](sera-2023formsx8xexhibit231.htm)</u> | <u>[X](sera-2023formsx8xexhibit231.htm)</u> |  |  |  |
| <u>[23.2](sera-2023formsx8xexhibit51.htm)</u> | <u>[Consent of](sera-2023formsx8xexhibit51.htm)</u><u>[Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)](sera-2023formsx8xexhibit51.htm)</u> | <u>[X](sera-2023formsx8xexhibit51.htm)</u> |  |  |  |
| <u>[24.1](#i190436f825d54556af3db629981a14a6_10)</u> | <u>[Power of Attorney (included on the signature page hereof)](#i190436f825d54556af3db629981a14a6_10)</u> | <u>[X](#i190436f825d54556af3db629981a14a6_10)</u> |  |  |  |
| <u>[99.1+](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[2021 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> |  | <u>[Form S-1/A (Exhibit 10.3)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[7/8/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> |
| <u>[99.2+](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[Form of Stock Option Agreement under the Registrant's 2021 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> |  | <u>[Form S-1/A (Exhibit 10.3)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[7/8/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> |
| <u>[99.3+](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[Form of Restricted Stock Unit Agreement under the Registrant's 2021 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> |  | <u>[Form S-1/A (Exhibit 10.3)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[7/8/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-3.htm)</u> |
| <u>[99.4+](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-4.htm)</u> | <u>[2021 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-4.htm)</u> |  | <u>[Form S-1/A (Exhibit 10.4)](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-4.htm)</u> | <u>[7/8/2021](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-4.htm)</u> | <u>[333-257038](https://www.sec.gov/Archives/edgar/data/1534969/000110465921089973/tm2110724d14_ex10-4.htm)</u> |
| <u>[107](sera-2023formsx8xexhibit107.htm)</u> | <u>[Filing Fee Table](sera-2023formsx8xexhibit107.htm)</u> | <u>[X](sera-2023formsx8xexhibit107.htm)</u> |  |  |  |

---

__________________________________

+ &nbsp;&nbsp;&nbsp;&nbsp;Denotes management contract or compensatory plan or arrangement

------

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized in Salt Lake City, Utah, on the 22nd day of March, 2023.

**SERA PROGNOSTICS, INC.**

By: <u>/s/ Gregory C. Critchfield, M.D., M.S.&nbsp;&nbsp;&nbsp;&nbsp;</u>

Gregory C. Critchfield, M.D., M.S.

Chairman, President and Chief Executive Officer

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints each of Gregory C. Critchfield, M.D., M.S. and Jay Moyes, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Gregory C. Critchfield, M.D., M.S. | Chairman, Chief Executive Officer, President and Director (*Principal Executive Officer*) | March 22, 2023 |
| Gregory C. Critchfield, M.D., M.S. | Chairman, Chief Executive Officer, President and Director (*Principal Executive Officer*) | March 22, 2023 |
| /s/ Jay Moyes | Chief Financial Officer (*Principal Financial and Accounting Officer*) | March 22, 2023 |
| Jay Moyes | Chief Financial Officer (*Principal Financial and Accounting Officer*) | March 22, 2023 |
| /s/ Joshua Phillips | Director | March 22, 2023 |
| Joshua Phillips | Director | March 22, 2023 |
| /s/ Mansoor Raza Mirza, M.D. | Director | March 22, 2023 |
| Mansoor Raza Mirza, M.D. | Director | March 22, 2023 |
| /s/ Ryan Trimble | Director | March 22, 2023 |
| Ryan Trimble | Director | March 22, 2023 |
| /s/ Kim Kamdar, Ph.D. | Director | March 22, 2023 |
| Kim Kamdar, Ph.D. | Director | March 22, 2023 |
| /s/ Marcus Wilson, Pharm.D. | Director | March 22, 2023 |
| Marcus Wilson, Pharm.D. | Director | March 22, 2023 |
| /s/ Zhenya Lindgardt | Director | March 22, 2023 |
| Zhenya Lindgardt | Director | March 22, 2023 |
| /s/ Sandra A.J. Lawrence | Director | March 22, 2023 |
| Sandra A.J. Lawrence | Director | March 22, 2023 |
| /s/ Jane F. Barlow, M.D. | Director | March 22, 2023 |
| Jane F. Barlow, M.D. | Director | March 22, 2023 |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table** 

**Form S-8** 

(Form Type)

**Sera Prognostics, Inc.** 

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | 2021 Equity Incentive Plan Class A Common Stock, par value $0.0001 per share | 457(c) and 457(h) | 1184507<sup>(2)</sup> | $4.13<sup>(4)</sup> | $4892013.91 | $0.0001102 | $539.10 |
| Equity | 2021 Employee Stock Purchase Plan Class A Common Stock, par value $0.0001 per share | 457(c) and 457(h) | 296126<sup>(3)</sup> | $4.13<sup>(4)</sup> | $1223000.38 | $0.0001102 | $134.77 |
| **Total Offering Amount** | **Total Offering Amount** | **Total Offering Amount** | **Total Offering Amount** |  | $6115014.29 |  | $673.87 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $673.87 |

---

(1) The maximum number of shares of common stock, par value $0.0001 per share ("Common Stock"), of Sera Prognostics, Inc. (the "Registrant") which may be sold upon the exercise of options or issuance of stock-based awards granted under the 2021 Equity Incentive Plan (the "2021 Plan") and the 2021 Employee Stock Purchase Plan (the "ESPP") is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2021 Plan and ESPP. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions.

(2) The number of shares of Common Stock of the Registrant stated above consists of 1,184,507 additional shares of Common Stock available for issuance under the 2021 Plan by operation of the 2021 Plan's "evergreen" provision.

(3) The number of shares of Common Stock of the Registrant stated above consists of 296,126 additional shares of Common Stock available for issuance under the ESPP by operation of the ESPP's "evergreen" provision.

(4) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the 2021 Plan and the ESPP are based on the average of the high and the low price of Registrant's Common Stock as reported on the Nasdaq Global Market as of a date (March 17, 2023) within five business days prior to filing this Registration Statement.

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![image_2.jpg](image_2.jpg) | One Financial Center<br>Boston, MA 02111<br>617 542 6000<br>mintz.com |

---

March 22, 2023

Sera Prognostics, Inc.

2749 East Parleys Way, Suite 200

Salt Lake City, UT 84109

&nbsp;&nbsp;&nbsp;&nbsp;Re:&nbsp;&nbsp;&nbsp;&nbsp;Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as legal counsel to Sera Prognostics, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of a Registration Statement on Form S-8 (the "Registration Statement"), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as amended (the "Securities Act"), of an aggregate of 1,480,633 shares (the "Shares") of the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"), including (i) 1,184,507 shares of the Company's Common Stock that may be issued pursuant to the Company's 2021 Equity Incentive Plan (the "2021 Plan"); and 296,126 shares of the Company's Common Stock that may be issued pursuant to the Company's 2021 Employee Stock Purchase Plan (the "ESPP", together with the 2021 Plan, the "Plans"). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

In connection with this opinion, we have examined the Company's Amended and Restated Certificate of Incorporation and Restated Bylaws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates of the Company's officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies, the authenticity of the originals of such copies, and the truth and correctness of any representations and warranties contained therein. In addition, we have assumed that the Company will receive any required consideration in accordance with the terms of the Plans.

Our opinion expressed herein is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

BOSTON&nbsp;&nbsp;&nbsp;&nbsp; LONDON&nbsp;&nbsp;&nbsp;&nbsp; LOS ANGELES&nbsp;&nbsp;&nbsp;&nbsp; NEW YORK&nbsp;&nbsp;&nbsp;&nbsp; SAN DIEGO&nbsp;&nbsp;&nbsp;&nbsp; SAN FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp; WASHINGTONMINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

------

---

| | |
|:---|:---|
| **MINTZ**<br>March 22, 2023<br>Page 2 | ![image_1.jpg](image_1.jpg) |

---

Based upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Plans, will be validly issued, fully paid and non-assessable.

We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Very truly yours,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*<u>/s/ Mintz, Levin, Cohn, Ferris,</u>*

*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Glovsky and Popeo, P.C.</u>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mintz, Levin, Cohn, Ferris,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glovsky and Popeo, P.C.

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) related to the registration of an additional 1,184,507 shares of the Registrant's Class A common stock pertaining to the 2021 Equity Incentive Plan and the registration of 296,126 shares of the Registrant's Class A common stock pertaining to the 2021 Employee Stock Purchase Plan of Sera Prognostics, Inc. of our report dated March 22, 2023, with respect to the financial statements of Sera Prognostics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Salt Lake City, Utah

March 22, 2023

<br>